476 related articles for article (PubMed ID: 16553576)
1. Sativex: clinical efficacy and tolerability in the treatment of symptoms of multiple sclerosis and neuropathic pain.
Barnes MP
Expert Opin Pharmacother; 2006 Apr; 7(5):607-15. PubMed ID: 16553576
[TBL] [Abstract][Full Text] [Related]
2. Sativex for the management of multiple sclerosis symptoms.
Perras C
Issues Emerg Health Technol; 2005 Sep; (72):1-4. PubMed ID: 16317825
[TBL] [Abstract][Full Text] [Related]
3. THC and CBD oromucosal spray (Sativex®) in the management of spasticity associated with multiple sclerosis.
Sastre-Garriga J; Vila C; Clissold S; Montalban X
Expert Rev Neurother; 2011 May; 11(5):627-37. PubMed ID: 21456949
[TBL] [Abstract][Full Text] [Related]
4. Tetrahydrocannabinol:Cannabidiol Oromucosal Spray for Multiple Sclerosis-Related Resistant Spasticity in Daily Practice.
Vermersch P; Trojano M
Eur Neurol; 2016; 76(5-6):216-226. PubMed ID: 27732980
[TBL] [Abstract][Full Text] [Related]
5. Sativex long-term use: an open-label trial in patients with spasticity due to multiple sclerosis.
Serpell MG; Notcutt W; Collin C
J Neurol; 2013 Jan; 260(1):285-95. PubMed ID: 22878432
[TBL] [Abstract][Full Text] [Related]
6. Sativex® (nabiximols) cannabinoid oromucosal spray in patients with resistant multiple sclerosis spasticity: the Belgian experience.
D'hooghe M; Willekens B; Delvaux V; D'haeseleer M; Guillaume D; Laureys G; Nagels G; Vanderdonckt P; Van Pesch V; Popescu V
BMC Neurol; 2021 Jun; 21(1):227. PubMed ID: 34157999
[TBL] [Abstract][Full Text] [Related]
7. Sativex(®) (tetrahydrocannabinol + cannabidiol), an endocannabinoid system modulator: basic features and main clinical data.
Vermersch P
Expert Rev Neurother; 2011 Apr; 11(4 Suppl):15-9. PubMed ID: 21449855
[TBL] [Abstract][Full Text] [Related]
8. Cost effectiveness of oromucosal cannabis-based medicine (Sativex®) for spasticity in multiple sclerosis.
Lu L; Pearce H; Roome C; Shearer J; Lang IA; Stein K
Pharmacoeconomics; 2012 Dec; 30(12):1157-71. PubMed ID: 23072659
[TBL] [Abstract][Full Text] [Related]
9. Drug-resistant MS spasticity treatment with Sativex(®) add-on and driving ability.
Freidel M; Tiel-Wilck K; Schreiber H; Prechtl A; Essner U; Lang M
Acta Neurol Scand; 2015 Jan; 131(1):9-16. PubMed ID: 25208898
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of the tolerability and efficacy of Sativex in multiple sclerosis.
Moreno Torres I; Sanchez AJ; Garcia-Merino A
Expert Rev Neurother; 2014 Nov; 14(11):1243-50. PubMed ID: 25331416
[TBL] [Abstract][Full Text] [Related]
11. Effect of Sativex on spasticity-associated symptoms in patients with multiple sclerosis.
Meuth SG; Vila C; Dechant KL
Expert Rev Neurother; 2015; 15(8):909-18. PubMed ID: 26166264
[TBL] [Abstract][Full Text] [Related]
12. Nabiximols in the treatment of spasticity, pain and urinary symptoms due to multiple sclerosis.
Podda G; Constantinescu CS
Expert Opin Biol Ther; 2012 Nov; 12(11):1517-31. PubMed ID: 22954177
[TBL] [Abstract][Full Text] [Related]
13. Oromucosal delta9-tetrahydrocannabinol/cannabidiol for neuropathic pain associated with multiple sclerosis: an uncontrolled, open-label, 2-year extension trial.
Rog DJ; Nurmikko TJ; Young CA
Clin Ther; 2007 Sep; 29(9):2068-79. PubMed ID: 18035205
[TBL] [Abstract][Full Text] [Related]
14. [There is evidence for the use of cannabinoids for symptomatic treatment of multiple sclerosis].
Bazinski H; Jensen HB; Stenager E
Ugeskr Laeger; 2015 May; 177(20):956-60. PubMed ID: 26535431
[TBL] [Abstract][Full Text] [Related]
15. Clinical efficacy and effectiveness of Sativex, a combined cannabinoid medicine, in multiple sclerosis-related spasticity.
Oreja-Guevara C
Expert Rev Neurother; 2012 Apr; 12(4 Suppl):3-8. PubMed ID: 22509985
[TBL] [Abstract][Full Text] [Related]
16. Tetrahydrocannabinol and cannabidiol oromucosal spray in resistant multiple sclerosis spasticity: consistency of response across subgroups from the SAVANT randomized clinical trial.
Meuth SG; Henze T; Essner U; Trompke C; Vila Silván C
Int J Neurosci; 2020 Dec; 130(12):1199-1205. PubMed ID: 32065006
[No Abstract] [Full Text] [Related]
17. Influence of Previous Failed Antispasticity Therapy on the Efficacy and Tolerability of THC:CBD Oromucosal Spray for Multiple Sclerosis Spasticity.
Haupts M; Vila C; Jonas A; Witte K; Álvarez-Ossorio L
Eur Neurol; 2016; 75(5-6):236-43. PubMed ID: 27160412
[TBL] [Abstract][Full Text] [Related]
18. Lack of effect of cannabis-based treatment on clinical and laboratory measures in multiple sclerosis.
Centonze D; Mori F; Koch G; Buttari F; Codecà C; Rossi S; Cencioni MT; Bari M; Fiore S; Bernardi G; Battistini L; Maccarrone M
Neurol Sci; 2009 Dec; 30(6):531-4. PubMed ID: 19768368
[TBL] [Abstract][Full Text] [Related]
19. [There is evidence for the use of cannabinoids for symptomatic treatment of multiple sclerosis].
Basinski H; Jensen HB; Stenager E
Ugeskr Laeger; 2014 Mar; 176(12A):. PubMed ID: 25350886
[TBL] [Abstract][Full Text] [Related]
20. Delta-9-tetrahydrocannabinol/cannabidiol (Sativex®): a review of its use in patients with moderate to severe spasticity due to multiple sclerosis.
Syed YY; McKeage K; Scott LJ
Drugs; 2014 Apr; 74(5):563-78. PubMed ID: 24671907
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
